Supercharged immune cells take on tough cancers in early human test
NCT ID NCT05103631
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in the lab to recognize a protein called GPC3 on cancer cells and to produce IL15, which helps them survive longer. The main goal is to find a safe dose and watch for side effects, while also checking if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CATCH T cells (genetically modified immune cells that target GPC3 and produce IL15)
- What this could lead to
- If it works, this could point toward a new treatment option for several hard-to-treat solid tumors that have not responded to standard therapy.
- What could go wrong
- This is a very early (Phase 1) and small (12 patients) trial focused on safety, not effectiveness. The cells may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMBRYONAL SARCOMA OF THE LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?